

Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/MFC816D812A1EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: MFC816D812A1EN

Abstracts

The 7 major marginal zone lymphoma markets reached a value of US\$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The marginal zone lymphoma market has been comprehensively analyzed in IMARC's new report titled "Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Marginal zone lymphoma is a type of non-Hodgkin lymphoma that arises from the marginal zone B cells in the lymphoid tissue. Some of the common symptoms include painless swelling of lymph nodes, particularly in the neck, armpits, or groin, as well as various nonspecific indications, like fatigue, night sweats, unexplained weight loss, fever, etc. In a few cases, the ailment may affect extranodal sites, leading to symptoms specific to the impacted organ, such as abdominal pain, gastrointestinal bleeding, respiratory difficulties, etc. The diagnosis of marginal zone lymphoma involves a combination of clinical evaluation, imaging studies, laboratory investigations, and histopathological examination. Several diagnostic imaging tests, including computed tomography (CT) scan and positron emission tomography (PET) scan, help in evaluating the extent of disease progression and identifying affected lymph nodes as well as extranodal sites. A definitive diagnosis is made through a lymph node or tissue biopsy, followed by a histopathological examination by a pathologist, which consists of microscopic analysis, immunohistochemistry, and flow cytometry to determine the presence of lymphoma cells and classify the specific subtype of the ailment.

The rising cases of specific genetic and molecular alterations that can disrupt normal cellular processes and interfere with the regulation of signaling pathways involved in cell

survival and immune responses are primarily driving the marginal zone lymphoma market. In addition to this, the escalating utilization of localized radiation therapy, which involves directing high-energy beams to the affected lymph nodes or organs, for controlling the disease and providing long-term remission is creating a positive outlook for the market. Moreover, the inflating adoption of stem cell transplantation for replacing diseased bone marrow with stem cells to allow the production of new, healthy blood cells is also bolstering the market growth. Additionally, the rising demand for antibody-drug conjugates for treating the ailment on account of their several associated benefits, including enhanced efficacy, targeted therapy, reduced systemic toxicity, etc., is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of cytogenetic analysis, such as chromosomal microarray analysis (CMA), since it aids in detecting chromosomal aberrations, including translocations or deletions, that can help in providing prognostic information and differentiating the ailment from other lymphoma subtypes, is expected to drive the marginal zone lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the marginal zone lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for marginal zone lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the marginal zone lymphoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the marginal zone lymphoma market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the marginal zone lymphoma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current marginal zone lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the marginal zone lymphoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the marginal zone lymphoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the marginal zone lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of marginal zone lymphoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with marginal zone lymphoma across the seven major markets?

What is the size of the marginal zone lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of marginal zone lymphoma?

What will be the growth rate of patients across the seven major markets?

Marginal Zone Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for marginal zone lymphoma drugs across the

seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the marginal zone lymphoma market?

What are the key regulatory events related to the marginal zone lymphoma market?

What is the structure of clinical trial landscape by status related to the marginal zone lymphoma market?

What is the structure of clinical trial landscape by phase related to the marginal zone lymphoma market?

What is the structure of clinical trial landscape by route of administration related to the marginal zone lymphoma market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MARGINAL ZONE LYMPHOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 MARGINAL ZONE LYMPHOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MARGINAL ZONE LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 MARGINAL ZONE LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 MARGINAL ZONE LYMPHOMA - UNMET NEEDS

10 MARGINAL ZONE LYMPHOMA - KEY ENDPOINTS OF TREATMENT

11 MARGINAL ZONE LYMPHOMA - MARKETED PRODUCTS

- 11.1 List of Marginal Zone Lymphoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Brukinsa (Zanubrutinib) - BeiGene
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Revlimid (Lenalidomide) - Celgene Corporation
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MARGINAL ZONE LYMPHOMA - PIPELINE DRUGS

- 12.1 List of Marginal Zone Lymphoma Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Loncastuximab tesirine - ADC Therapeutics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Tafasitamab - Incyte Corporation/MorphoSys
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
 - 12.1.3 Orelabrutinib - InnoCare Pharma
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. MARGINAL ZONE LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MARGINAL ZONE LYMPHOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 MARGINAL ZONE LYMPHOMA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Marginal Zone Lymphoma - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Marginal Zone Lymphoma - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Marginal Zone Lymphoma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Marginal Zone Lymphoma - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Marginal Zone Lymphoma - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Marginal Zone Lymphoma - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Marginal Zone Lymphoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Marginal Zone Lymphoma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Marginal Zone Lymphoma - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Marginal Zone Lymphoma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Marginal Zone Lymphoma - Access and Reimbursement Overview

16 MARGINAL ZONE LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MARGINAL ZONE LYMPHOMA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 MARGINAL ZONE LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/MFC816D812A1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MFC816D812A1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

